ClouDr Group (FRA:H3L) Forward PE Ratio: 3.82 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H3L ClouDr Group Ltd FRA:H3L
48 GF Score
Price €0.05
GF Value €0.08
! 9 Warning Signs
View Full Analysis

What is ClouDr Group Forward PE Ratio?

ClouDr Group FRA:H3L 48 Forward PE Ratio is 3.82 as of Aug. 27, 2026. GuruFocus rates FRA:H3L with a GF Score™ of 48/100 and a GF Value™ of €0.08. The stock has 9 warning signs investors should review. Among 50 Medical Distribution companies, ClouDr Group ranks better than 94% on this metric.

ClouDr Group's Forward PE Ratio for today is 3.82.

ClouDr Group's PE Ratio without NRI for today is 0.00.

ClouDr Group's PE Ratio (TTM) for today is 0.00.


ClouDr Group  (FRA:H3L) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


ClouDr Group Forward PE Ratio Related Terms


ClouDr Group Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for ClouDr Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClouDr Group Forward PE Ratio Chart

ClouDr Group Annual Data
Trend 2025-12
Forward PE Ratio
7.57

ClouDr Group Semi-Annual Data
2025-12
Forward PE Ratio 7.57

FRA:H3L vs MCK, COR, CAH: Forward PE Ratio Comparison

For the Medical Distribution subindustry, ClouDr Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClouDr Group Forward PE Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, ClouDr Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where ClouDr Group's Forward PE Ratio falls into.


FRA:H3L
48GF Score
ClouDr Group Ltd FRA:H3L
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ClouDr Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 3.82 mean?
ClouDr Group (FRA:H3L) has a Forward PE Ratio of 3.82 as of Aug. 27, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on ClouDr Group and its competitors. According to the industry distribution chart, ClouDr Group ranks #3 out of 50 companies in the Medical Distribution industry, placing it in the top 6%.
Is ClouDr Group's Forward PE Ratio too high?
ClouDr Group's current Forward PE Ratio is 3.82. The Medical Distribution industry median Forward PE Ratio is 14.90. ClouDr Group's value of 3.82 is 74.4% below this industry median. Based on the distribution chart, ClouDr Group ranks #3 out of 50 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's Forward PE Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ClouDr Group ranks #3 out of 50 companies for Forward PE Ratio. This places ClouDr Group in the top 6% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 14.90. ClouDr Group's value of 3.82 is 74.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Distribution company?
The median Forward PE Ratio among Medical Distribution companies is 14.90, based on 50 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ClouDr Group's current Forward PE Ratio of 3.82 is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on ClouDr Group and its competitors. For the Medical Distribution industry, the median Forward PE Ratio is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClouDr Group's current Forward PE Ratio is 3.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current Forward PE Ratio of 3.82. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current Forward PE Ratio is 3.82 and 74.4% below the Medical Distribution industry median of 14.90. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current Forward PE Ratio is 3.82 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClouDr Group (FRA:H3L) Overvalued in 2026?

Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued. The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.

Key valuation signals for FRA:H3L:

  • Forward PE Ratio: 3.82
  • GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
  • GF Score™: 48/100 with 9 warning signs
  • Industry Position: 74.4% below the Medical Distribution median (#3 of 50)

No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ClouDr Group Business Description

Other Exchanges 09955:Hong Kong
Address No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score

Get the complete analysis for FRA:H3L

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price
€0.08
GF Value